Compare Carvana Co (CVNA) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Cytokinetics Inc — how do they compare? Carvana Co trades at $63.7 (market cap $69.55B), while Cytokinetics Inc trades at $62.9 (market cap $8.62B). The key difference: Carvana Co is far larger — about 8.1× Cytokinetics Inc's market cap, and Carvana Co is more actively traded (7,671,750 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Cytokinetics Inc for 19 Days on average.
| CVNA | CYTK | |
|---|---|---|
Market Cap | $69.55B | $8.62B |
Volume | 7,671,750 | 2,594,626 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $87.26 |
52-Week Low | $56.27 | $54.76 |
Typical Hold Time | 28 Days | 19 Days |
Enterprise Value | $72.04B | $8.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $64.26, up 2.39% on the day, showing resilience amid a bearish technical signal. The company reported strong revenue growth to $20.32B in 2025 with net income of $1.41B, and has beaten EPS estimates for three consecutive quarters. Positive analyst sentiment is highlighted by a consensus price target of $84.07, though technical indicators suggest near-term caution with key support at $61.
Outlook remains positive due to robust earnings beats and expansion initiatives, but risks include high debt levels and competitive pressures. The stock offers growth potential if operational execution continues, yet investors should monitor cash flow sustainability and market volatility.
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
